Provectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page
June 01 2016 - 6:00AM
Business Wire
New Channels Reflect Company Advancement and
Evolution
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
www.provectusbio.com), a clinical-stage oncology and dermatology
biopharmaceutical company ("Provectus" or “The Company”), announced
today the launch of its newly redesigned website at
www.Provectusbio.com as well as the company’s official Facebook
page at www.facebook.com/Provectusbio.
The new website has been built to answer the needs of expanding
audiences as well as provide existing stakeholders with more
detailed company and product information. The interactive,
user-friendly site offers easy access to key information, including
the story of Rose Bengal, real time stockholder updates and
available clinical trials, to name a few. The responsive design
effectively allows visitors to engage in their preferred channel of
communication, from tablet to mobile and on computer.
“Our website has always been an important way for us to update
our audiences about the implications of PV-10 and the vision of
Provectus,” said Peter Culpepper, Interim CEO and COO of Provectus
Biopharmaceuticals, Inc. “The new site now reflects the bright
future of the company with a patient-focus, modern styling and
seamless navigation.”
In addition, Provectus launched the official company Facebook
page at www.facebook.com/Provectusbio. As another key milestone in
expanding the company’s channels for engagement and delivering news
updates, the page is an important step toward fulfilling the
company’s more long-term patient-centric vision.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10 is a novel
investigational drug for cancer: melanoma, breast cancer and
cancers of the liver. The Company has received orphan drug
designations from the FDA for its melanoma and hepatocellular
carcinoma indications. PH-10, its topical investigational drug for
dermatology, is undergoing clinical testing for psoriasis and
atopic dermatitis. Provectus has completed Phase 2 trials of PV-10
as a therapy for metastatic melanoma, and of PH-10 as a topical
treatment for atopic dermatitis and psoriasis. Information about
these and the Company's other clinical trials can be found at the
NIH registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company's website at
www.provectusbio.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2015) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the
process of being further developed in conjunction with mechanism of
action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160601005431/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30Interim CEO, COOorPorter, LeVay & Rose,
Inc.Marlon Nurse, DM, 212-564-4700SVP – Investor RelationsorAllison
+ PartnersTodd Aydelotte, 646-428-0644Managing Director – Media
Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From May 2023 to May 2024